Autolus Therapeutics (NASDAQ:AUTL) Hits New 52-Week Low – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $2.07 and last traded at $2.25, with a volume of 1651083 shares traded. The stock had previously closed at $2.18.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $7.00 to $7.60 in a report on Monday, November 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, December 5th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics currently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Trading Up 2.2 %

The company has a market cap of $612.02 million, a price-to-earnings ratio of -1.90 and a beta of 1.99. The stock’s 50 day moving average price is $3.23 and its 200 day moving average price is $3.73.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the business earned ($0.26) EPS. On average, equities analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC lifted its stake in shares of Autolus Therapeutics by 9.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after purchasing an additional 3,740 shares in the last quarter. Wealth Effects LLC raised its stake in shares of Autolus Therapeutics by 19.5% during the second quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock valued at $171,000 after purchasing an additional 8,000 shares during the period. Bellevue Group AG lifted its position in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares in the last quarter. State Street Corp boosted its position in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after buying an additional 10,401 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the second quarter valued at about $43,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.